Implementation of State Prescription Drug Monitoring Program Mandatory Checking Requirements and Prescribed Opioid Analgesic Use Among Women With and Without HIV in The Women’s Interagency HIV Study: A Longitudinal Observational Study Using Staggered Adoption Difference-in-differences Analyses
Authors:
- Danielle F. HaleyDHDanielle F. Haley
- Vivian F. GoVGVivian F. Go
- Michael R. WinterMWMichael R. Winter
- Kathryn D. ThompsonKTKathryn D. Thompson
- Ni PengshengNPNi Pengsheng
- Michael P. WilliamsMWMichael P. Williams
- Andrew EdmondsAEAndrew Edmonds
- Alicia DiggsADAlicia Diggs
- David B. HannaDHDavid B. Hanna
- Mardge CohenMCMardge Cohen
- Mirjam-Colette KempfMKMirjam-Colette Kempf
- Phyllis TienPTPhyllis Tien
- 18 July 2026
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- p. 1-12
Abstract
Implementation of prescription drug monitoring programs requiring mandatory checking when prescribing or dispensing reduces opioid analgesic (OA) prescribing. OA receipt varies by individual-level factors, including HIV status. Mandatory prescription drug monitoring program checking requirements (MPDMPs) may exacerbate inequities if prompts trigger biased decision-making around clinical need for OAs. We examined whether MPDMP implementation was associated with changes in self-reported use of prescribed OAs among women and whether associations varied by HIV status. We conducted staggered adoption difference-in-differences analyses using 11 semi-annual data waves (2014–2019) from the Women’s Interagency HIV Study, a multisite observational cohort of women with and without HIV. Among 1,720 women, 71% had HIV; 61% were non-Hispanic Black. €The percentage of participants reporting prescribed OA use at baseline was comparable for women with HIV (16.5%) and without HIV (15.1%) but varied by race/ethnicity (non-Hispanic white 22.9%; non-Hispanic Black 13.6%; Hispanic 14.1%). In the adjusted model controlling for baseline age, race/ethnicity, education, HIV status, and census tract socioeconomic characteristics, MPDMP implementation was associated with a 3.6% percentage-point reduction in the probability prescribed OA use (average treatment effect on the treated = -0.036, 95% confidence interval − 0.060 to − 0.011). There was no significant evidence of variation by HIV status. MPDMPs reduce prescribed OA use in individuals. MPDMP implementation raises important questions about the role of provider bias in balancing reductions in overprescribing with maintaining access to OAs for those with special medical needs. Future research examining subgroups is needed to fully characterize MPDMP benefits and harms.Keywords
Funding Information
- National Institute on Drug Abuse (K01DA046307)
- National Heart, Lung, and Blood Institute (U01-HL146241)
- National Institutes of Health (U01-HL146204)
- National Institutes of Health (U01-HL146193)
- National Institutes of Health (U01-HL146242)
- National Institutes of Health (U01-HL146245)
- National Institutes of Health (U01-HL146205)
- National Institutes of Health (U01-HL146203)
- National Institutes of Health (U01-HL146192)
This publication has 37 references indexed in Scilit:
- State Policies Regulating Law Enforcement Access to Prescription Drug Monitoring Program Testosterone Prescription DataJAMA, 2024
- Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019JAMA Network Open, 2023
- Intersectional Discrimination in HIV Healthcare Settings Among Persons with Diagnosed HIV in the United States, Medical Monitoring Project, 2018–2019AIDS and Behavior, 2023
- Patient and Provider Perspectives on HIV Stigma in Healthcare Settings in Underserved Areas of the US South: A Mixed Methods StudyAIDS and Behavior, 2021
- Association of Patient Race and Ethnicity With Differences in Opioid Prescribing by Primary Care Physicians for Older Adults With New Low Back PainJAMA Health Forum, 2021
- Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic OncologistJAMA Oncology, 2020
- HIV Physicians and Chronic Opioid Therapy: It’s Time to Raise the BarAIDS and Behavior, 2018
- Frequent Occurrence of Pain and Prescription Opioid Use for Treatment of Pain Among Women with and at Risk for HIV InfectionAIDS and Behavior, 2017
- Understanding HIV-Related Stigma Among Women in the Southern United States: A Literature ReviewAIDS and Behavior, 2016
- Mandatory Use of Prescription Drug Monitoring ProgramsJAMA, 2015